Novartis focuses on oncology pipeline, shares track SMI pharma peers
26.06.2026 - 16:01:44 | ad-hoc-news.de
By Julia Schmitt, Sector & Peer Group desk. Reviewed prior to publication on 2026-06-26, 16:01.
Novartis (CH0012005267) stands as one of the largest pharma groups in the Swiss Market Index, with a strong footprint in oncology and immunology. The stock trades via a primary listing on SIX Swiss Exchange in Zurich, and an ADR on the NYSE under the ticker NVS.
What market data shows today
On the NYSE, Novartis ADRs last closed at 155.06 US dollars on June 25, 2026, reflecting a 1.27 percent gain for that session. The market capitalization based on that close stands around 295.9 billion US dollars, keeping Novartis firmly in the global large-cap pharma cohort.
In Swiss trading, the Novartis shares recently changed hands around 134.20 Swiss francs, according to intraday data from a Swiss equity quote platform on June 25, 2026. This puts the stock in line with other SMI constituents after the index itself notched a fresh high in late June.
Analyst stance and sector comparison
Analyst consensus on Novartis remains broadly constructive but cautious, with a blended rating near hold and an average 12-month price target around 143.65 US dollars for the ADR, according to one aggregated research overview. That target sits modestly below the latest NYSE close, indicating limited upside in the current models.
Within large-cap European pharma, Novartis is frequently compared with Swiss peer Roche and Danish group Novo Nordisk, whose obesity drug franchise has driven strong share price gains in recent quarters. This peer context keeps investor attention on Novartis oncology, immunology and radioligand therapy pipeline as potential relative performance drivers.
All news and analysis on the Novartis shares
Further updates, regulatory filings and price data on Novartis are available in the dedicated topic section and via the company’s investor relations page.
The products behind the stock
Novartis generates most of its revenue from patented prescription medicines in oncology, immunology, neuroscience and cardiovascular disease, complemented by Sandoz-branded generics prior to the recent spin-off. Flagship oncology products include targeted therapies and radioligand treatments, such as Pluvicto for advanced prostate cancer, which management has highlighted as a multi-billion dollar opportunity.
Where the stock trades today
The Novartis shares (CH0012005267) trade on SIX Swiss Exchange, with the Swiss line recently quoted around 134.20 Swiss francs on June 25, 2026, while the NYSE ADR closed at 155.06 US dollars on the same date.
Key data on the Novartis shares
- Company: Novartis AG
- ISIN: CH0012005267
- WKN: 904278
- Ticker: NVS (ADR), NOVN (SIX)
- Trading venue: SIX Swiss Exchange / NYSE ADR
- Price (as of 2026-06-25, 16:00): 134.20 CHF (SIX), 155.06 USD (NYSE ADR)
- Market cap: 295.9 billion USD (as of 2026-06-25)
- Sector / industry: Pharmaceuticals / Biotechnology
- Index membership: SMI, STOXX Europe 50, STOXX Europe 600
- Next earnings date: not officially scheduled
Disclaimer: This text is for informational purposes only and does not constitute investment advice, a recommendation to buy or sell securities, or any other form of financial guidance. All data are based on sources cited in the text and may change over time.
